Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Bipyramidal gold nanoparticles-assisted plasmonic photothermal therapy for ocular applications.
J Mater Chem B
January 2025
Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Department of Ophthalmology, Reina Sofia University Hospital and University of Cordoba, 14004 Cordoba, Spain.
Gold nanoparticles (AuNPs) play a key role in the field of nanomedicine due to their fascinating plasmonic properties as well as their great biocompatibility. An intriguing application is the use of plasmonic photothermal therapy (PPTT) mediated by anisotropic AuNPs irradiated with a near-infrared (NIR) laser for treating ocular diseases in ophthalmology. For this purpose, bipyramidal-shaped AuNPs (BipyAu), which were surface-functionalized with three different organic ligands (citrate, polystyrene sulphonate (PSS), and cetyltrimethylammonium bromide (CTAB)), were synthesized.
View Article and Find Full Text PDFCongenital Factor VII Deficiency: A Case Study of Four Family Members.
Cureus
December 2024
Hematology, Avicenna Military Hospital, Marrakesh, MAR.
Congenital factor VII (FVII) deficiency is a rare genetic disorder with autosomal recessive inheritance, characterized by molecular and clinical heterogeneity. This article reports four Moroccan cases of FVII deficiency within the same family, two of which were associated with Gilbert's syndrome. The index case was a 15-year-old girl with a history of menorrhagia and jaundice.
View Article and Find Full Text PDFImpact of pathogenic mutations of the GLUT1 glucose transporter on solute carrier dynamics using ComDYN enhanced sampling.
F1000Res
January 2025
Dept. Computer Science, Integrative Bioinformatics, Vrije Universiteit, Amsterdam, The Netherlands.
The solute carrier (SLC) family of membrane proteins is a large class of transporters for many small molecules that are vital for cellular function. Several pathogenic mutations are reported in the glucose transporter subfamily SLC2, causing Glut1-deficiency syndrome (GLUT1DS1, GLUT1DS2), epilepsy (EIG2) and cryohydrocytosis with neurological defects (Dystonia-9). Understanding the link between these mutations and transporter dynamics is crucial to elucidate their role in the dysfunction of the underlying transport mechanism, which we investigate using molecular dynamics simulations.
View Article and Find Full Text PDFOral Versus Injectable Vitamin D Therapy for Treating Nutritional Rickets in Indian Children: A Comparative Study.
Indian J Orthop
February 2025
Department of Orthopaedics, JSS Medical College, Mysore, 570004 India.
Background: Rickets is a common metabolic bone disease in children, primarily caused by vitamin D deficiency. This study aimed to compare the efficacy of oral weekly vitamin D supplementation and injectable stoss therapy in treating nutritional rickets in Indian children.
Methods: This prospective, randomized, controlled trial was conducted over 18 months at a tertiary care center.
First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours.
BMJ Oncol
May 2024
Sarah Cannon Cancer Institute, Nashville, Tennessee, USA.
Objective: The arginase inhibitor INCB001158 was evaluated for safety (primary endpoint) in locally advanced or metastatic solid tumours; pharmacokinetics, pharmacodynamics and efficacy were also assessed.
Methods And Analysis: In this non-randomised, open-label, three-part phase 1 study, INCB001158 was orally administered two times per day as monotherapy or in combination with intravenous pembrolizumab 200 mg every 3 weeks. Dose expansion was conducted in tumour-type cohorts (with or without prior anti-PD-1/PD-L1 (programmed death protein 1/programmed death ligand 1) therapy).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!